利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.032 秒)

    Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model
    5.
    发明授权
    Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model 有权
    尿路上皮癌尿路上皮分化：膀胱癌干细胞模型

    公开(公告)号：US08784772B2

    公开(公告)日：2014-07-22

    申请号：US12079078

    申请日：2008-03-24

    申请人： David M. Berman ,  William Matsui ,  Xiaobing He

    发明人： David M. Berman ,  William Matsui ,  Xiaobing He

    IPC分类号： A61K51/08 ,  A61P35/00 ,  A61K39/395 ,  A61B5/055 ,  A61K49/00 ,  A61K51/10 ,  G01N33/48 ,  C12Q1/00

    CPC分类号： G01N33/57484 ,  A61K49/0002

    摘要： The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.

    摘要翻译： 本发明提供了在有需要的患者（例如，人类患者）中治疗癌症的方法，所述方法包括施用治疗有效的方案，所述方案包括向有需要的患者施用靶向67层粘连蛋白受体（ 67LR）。 在一个具体实施方案中，靶向67LR的化合物是抗体或抗体片段。 特别地，本发明提供了一种治疗癌症的方法，包括向有需要的患者施用与67LR结合的抗体。 本发明还提供了一种治疗癌症的方法，包括向有需要的患者施用抗体缀合物，其中所述抗体缀合物包含与治疗剂，蛋白质毒素，细胞毒性剂或其它部分连接的67LR结合的抗体。 本发明提供了用于治疗癌症的药物组合物，其包含以有效减少患者的癌症干细胞和/或癌细胞的量结合67LR的抗体。 本发明还提供了用于根据67LR的表达来检测和监测癌症干细胞的方法。

    CANCER STEM CELL EXPRESSION PATTERNS AND COMPOUNDS TO TARGET CANCER STEM CELLS
    7.
    发明申请
    CANCER STEM CELL EXPRESSION PATTERNS AND COMPOUNDS TO TARGET CANCER STEM CELLS 审中-公开
    癌症干细胞表达模式和化合物靶向癌细胞

    公开(公告)号：US20110020221A1

    公开(公告)日：2011-01-27

    申请号：US12757649

    申请日：2010-04-09

    申请人： David M. Berman ,  Xiaobing He ,  William Matsui

    发明人： David M. Berman ,  Xiaobing He ,  William Matsui

    IPC分类号： A61K39/395 ,  A61P35/00 ,  A61K51/00 ,  A61P35/02

    CPC分类号： C07K16/30 ,  A61K47/6851 ,  A61K51/1045

    摘要： Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.

    摘要翻译： 本文描述的是在癌症干细胞中表达的治疗靶点和通过用抗体，化合物，核酸或其它治疗剂靶向这样的细胞来治疗和诊断癌症的方法。 在本文所述的一个实施方案中，基于癌症干细胞靶标的鉴定提供了用于治疗癌症的治疗剂。 本发明还包括癌症治疗和癌症干细胞靶向治疗的治疗靶标。 本发明包括通过施用靶向癌症干细胞的化合物或试剂来治疗癌症。